Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 9/20 | 0.63 |
| ▸ | FOLR1 | P15328 | 7/20 | 0.63 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 0.63 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.63 |
| ▸ | GART | P22102 | 6/20 | 0.63 |
| ▸ | DHFR | P00374 | 4/20 | 0.63 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.63 |
| ▸ | ATIC | P31939 | 2/20 | 0.63 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.63 |
| ▸ | FRK | P42685 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084411 | 0.92 | TYMS (0.62) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL18738460 | 0.90 | DHFR (0.78) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12180576 | 0.88 | TYMS (0.80) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL18738491 | 0.83 | DHFR (0.75) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL14008868 | 0.81 | TYMS (0.69) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL24413672 | 0.79 | GART (0.85) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL23117778 | 0.79 | TYMS (0.69) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL23117779 | 0.79 | TYMS (0.69) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12264580 | 0.79 | TYMS (0.69) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL19758225 | 0.78 | GART (0.87) | TYMSFOLR1SLC46A1SLC19A1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | GPI, SLC2A1, SLC2A4 | TYMS 120/4885FOLR1 115/4885SLC46A1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.